In 2026, R&D speed is about learning faster, scaling responsibly and reducing risk in an increasingly complex system, says ...

Viatris (VTRS) targets 5–6% revenue and 9–10% EPS CAGR through 2030, backed by launches, pipeline and $11B M&A cash. Click here to read my most recent analysis.

NASA's Artemis II mission is sending humans back to the moon for the first time since the Apollo era. Here are the reasons ...

There’s a very insightful formulation on page 65 of the brilliant historian Luke Kemp’s indispensable book Goliath’s Curse: The History and Future of ...

News footage these days sometimes shows wild horses crowding dry rangelands in the American West or deer wandering through ...

Former Olympian and European Indoor Champion Petr Svoboda has set a new Masters (M40) world-level performance in the 60-meter hurdles (7.78 sec.), completing a remarkable return to elite competition ...

Private equity in agtech participation remains selective but it is increasing, according to a new report from Verdant Partners.

AI is transforming dairy operations and boosting investor confidence. One cheese manufacturer achieved a 1% to 3% margin improvement—and millions in additional revenue—through AI-driven yield ...

Shenouda With me on today's call are Relmada Therapeutics, Inc.'s CEO, Dr. Sergio Traversa, who will briefly provide a summary of recent business highlights; Dr. Raj S. Pruthi, Relmada Therapeutics, ...

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2025 Earnings Call Transcript March 19, 2026 Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS, expectations were ...

Exozymes are advanced enzymes enhanced through bioengineering and AI to thrive in a bioreactor without using living cells. Exozymes can replace toxic petrochemical processes and inefficient ...

Experts reveal the best winter skin treatments—from lasers to RF microneedling and peels—to repair sun damage, boost collagen and reveal glowing skin by spring.